PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy
Abstract
:1. Introduction
2. PPARγ as a Molecular Target for Breast Cancer Therapy
3. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Guan, Y.; Breyer, M.D. Peroxisome Proliferator-Activated Receptors (Ppars): Novel Therapeutic Targets in Renal Disease. Kidney Int. 2001, 60, 14–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Quintao, N.L.M.; Santin, J.R.; Stoeberl, L.C.; Correa, T.P.; Melato, J.; Costa, R. Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: Ppargamma Agonists as a Promising Tool. Front. Neurosci. 2019, 13, 907. [Google Scholar] [CrossRef] [PubMed]
- Tontonoz, P.; Spiegelman, B.M. Fat and Beyond: The Diverse Biology of Ppargamma. Annu. Rev. Biochem. 2008, 77, 289–312. [Google Scholar] [CrossRef]
- Kroker, A.J.; Bruning, J.B. Review of the Structural and Dynamic Mechanisms of Ppargamma Partial Agonism. PPAR Res. 2015, 2015, 816856. [Google Scholar] [CrossRef] [Green Version]
- Powell, E.; Kuhn, P.; Xu, W. Nuclear Receptor Cofactors in Ppargamma-Mediated Adipogenesis and Adipocyte Energy Metabolism. PPAR Res. 2007, 2007, 53843. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zieleniak, A.; Wojcik, M.; Wozniak, L.A. Structure and Physiological Functions of the Human Peroxisome Proliferator-Activated Receptor Gamma. Arch. Immunol. Exp. 2008, 56, 331–345. [Google Scholar] [CrossRef] [PubMed]
- Bonofiglio, D.; Santoro, A.; Martello, E.; Vizza, D.; Rovito, D.; Cappello, A.R.; Barone, I.; Giordano, C.; Panza, S.; Catalano, S.; et al. Mechanisms of Divergent Effects of Activated Peroxisome Proliferator-Activated Receptor-Gamma on Mitochondrial Citrate Carrier Expression in 3t3-L1 Fibroblasts and Mature Adipocytes. Biochim. Biophys. Acta 2013, 1831, 1027–1036. [Google Scholar] [CrossRef]
- He, W.; Barak, Y.; Hevener, A.; Olson, P.; Liao, D.; Le, J.; Nelson, M.; Ong, E.; Olefsky, J.M.; Evans, R.M. Adipose-Specific Peroxisome Proliferator-Activated Receptor Gamma Knockout Causes Insulin Resistance in Fat and Liver but Not in Muscle. Proc. Natl. Acad. Sci. USA 2003, 100, 15712–15717. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seo, J.B.; Moon, H.M.; Kim, W.S.; Lee, Y.S.; Jeong, H.W.; Yoo, E.J.; Ham, J.; Kang, H.; Park, M.G.; Steffensen, K.R.; et al. Activated Liver X Receptors Stimulate Adipocyte Differentiation through Induction of Peroxisome Proliferator-Activated Receptor Gamma Expression. Mol. Cell Biol. 2004, 24, 3430–3444. [Google Scholar] [CrossRef] [Green Version]
- Belfiore, A.; Genua, M.; Malaguarnera, R. Ppar-Gamma Agonists and Their Effects on Igf-I Receptor Signaling: Implications for Cancer. PPAR Res. 2009, 2009, 830501. [Google Scholar] [CrossRef] [Green Version]
- Lefebvre, A.M.; Chen, I.; Desreumaux, P.; Najib, J.; Fruchart, J.C.; Geboes, K.; Briggs, M.; Heyman, R.; Auwerx, J. Activation of the Peroxisome Proliferator-Activated Receptor Gamma Promotes the Development of Colon Tumors in C57bl/6j-Apcmin/+ Mice. Nat. Med. 1998, 4, 1053–1057. [Google Scholar] [CrossRef]
- Rochel, N.; Krucker, C.; Coutos-Thévenot, L.; Osz, J.; Zhang, R.; Guyon, E.; Zita, W.; Vanthong, S.; Hernandez, O.A.; Bourguet, M.; et al. Recurrent Activating Mutations of Pparγ Associated with Luminal Bladder Tumors. Nat. Commun. 2019, 10, 253. [Google Scholar] [CrossRef]
- Saez, E.; Tontonoz, P.; Nelson, M.C.; Alvarez, J.G.; Ming, U.T.; Baird, S.M.; Thomazy, V.A.; Evans, R.M. Activators of the Nuclear Receptor Ppargamma Enhance Colon Polyp Formation. Nat. Med. 1998, 4, 1058–1061. [Google Scholar] [CrossRef] [PubMed]
- Bonofiglio, D.; Qi, H.; Gabriele, S.; Catalano, S.; Aquila, S.; Belmonte, M.; Ando, S. Peroxisome Proliferator-Activated Receptor Gamma Inhibits Follicular and Anaplastic Thyroid Carcinoma Cells Growth by Upregulating P21cip1/Waf1 Gene in a Sp1-Dependent Manner. Endocr. Related Cancer 2008, 15, 545–557. [Google Scholar] [CrossRef] [PubMed]
- Fujimura, S.; Suzumiya, J.; Nakamura, K.; Ono, J. Effects of Troglitazone on the Growth and Differentiation of Hematopoietic Cell Lines. Int. J. Oncol. 1998, 13, 1263–1267. [Google Scholar] [CrossRef] [PubMed]
- Kotta-Loizou, I.; Giaginis, C.; Theocharis, S. The Role of Peroxisome Proliferator-Activated Receptor-Gamma in Breast Cancer. Anti-Cancer Agents Med. Chem. 2012, 12, 1025–1044. [Google Scholar] [CrossRef]
- Tsubouchi, Y.; Sano, H.; Kawahito, Y.; Mukai, S.; Yamada, R.; Kohno, M.; Inoue, K.; Hla, T.; Kondo, M. Inhibition of Human Lung Cancer Cell Growth by the Peroxisome Proliferator-Activated Receptor-Gamma Agonists through Induction of Apoptosis. Biochem. Biophys. Res. Commun. 2000, 270, 400–405. [Google Scholar] [CrossRef]
- Bonofiglio, D.; Gabriele, S.; Aquila, S.; Catalano, S.; Gentile, M.; Middea, E.; Giordano, F.; Ando, S. Estrogen Receptor Alpha Binds to Peroxisome Proliferator-Activated Receptor Response Element and Negatively Interferes with Peroxisome Proliferator-Activated Receptor Gamma Signaling in Breast Cancer Cells. Clin. Cancer Res. 2005, 11, 6139–6147. [Google Scholar] [CrossRef] [Green Version]
- Bonofiglio, D.; Gabriele, S.; Aquila, S.; Qi, H.; Belmonte, M.; Catalano, S.; Ando, S. Peroxisome Proliferator-Activated Receptor Gamma Activates Fas Ligand Gene Promoter Inducing Apoptosis in Human Breast Cancer Cells. Breast Cancer Res. Treat. 2009, 113, 423–434. [Google Scholar] [CrossRef] [Green Version]
- Rovito, D.; Gionfriddo, G.; Barone, I.; Giordano, C.; Grande, F.; De Amicis, F.; Lanzino, M.; Catalano, S.; Ando, S.; Bonofiglio, D. Ligand-Activated Ppargamma Downregulates Cxcr4 Gene Expression through a Novel Identified Ppar Response Element and Inhibits Breast Cancer Progression. Oncotarget 2016, 7, 65109–65124. [Google Scholar] [CrossRef] [Green Version]
- Rovito, D.; Giordano, C.; Plastina, P.; Barone, I.; De Amicis, F.; Mauro, L.; Rizza, P.; Lanzino, M.; Catalano, S.; Bonofiglio, D.; et al. Omega-3 Dha- and Epa-Dopamine Conjugates Induce Ppargamma-Dependent Breast Cancer Cell Death through Autophagy and Apoptosis. Biochim. Biophys. Acta 2015, 1850, 2185–2195. [Google Scholar] [CrossRef]
- Wang, Y.; Zhu, M.; Yuan, B.; Zhang, K.; Zhong, M.; Yi, W.; Xu, X.; Duan, X. Vsp-17, a New Ppargamma Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer Via Upregulating the Expression of E-Cadherin. Molecules 2018, 23, 121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Augimeri, G.; Giordano, C.; Gelsomino, L.; Plastina, P.; Barone, I.; Catalano, S.; Ando, S.; Bonofiglio, D. The Role of Ppargamma Ligands in Breast Cancer: From Basic Research to Clinical Studies. Cancers 2020, 12, 2623. [Google Scholar] [CrossRef] [PubMed]
- Bonofiglio, D.; Aquila, S.; Catalano, S.; Gabriele, S.; Belmonte, M.; Middea, E.; Qi, H.; Morelli, C.; Gentile, M.; Maggiolini, M.; et al. Peroxisome Proliferator-Activated Receptor-Gamma Activates P53 Gene Promoter Binding to the Nuclear Factor-Kappab Sequence in Human Mcf7 Breast Cancer Cells. Mol. Endocrinol. 2006, 20, 3083–3092. [Google Scholar] [CrossRef] [PubMed]
- Bonofiglio, D.; Cione, E.; Qi, H.; Pingitore, A.; Perri, M.; Catalano, S.; Vizza, D.; Panno, M.L.; Genchi, G.; Fuqua, S.A.; et al. Combined Low Doses of Ppargamma and Rxr Ligands Trigger an Intrinsic Apoptotic Pathway in Human Breast Cancer Cells. Am. J. Pathol. 2009, 175, 1270–1280. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Catalano, S.; Mauro, L.; Bonofiglio, D.; Pellegrino, M.; Qi, H.; Rizza, P.; Vizza, D.; Bossi, G.; Ando, S. In Vivo and In Vitro Evidence That Ppargamma Ligands Are Antagonists of Leptin Signaling in Breast Cancer. Am. J. Pathol. 2011, 179, 1030–1040. [Google Scholar] [CrossRef]
- Grommes, C.; Landreth, G.E.; Heneka, M.T. Antineoplastic Effects of Peroxisome Proliferator-Activated Receptor Gamma Agonists. Lancet Oncol. 2004, 5, 419–429. [Google Scholar] [CrossRef]
- Wang, C.; Fu, M.; D’Amico, M.; Albanese, C.; Zhou, J.N.; Brownlee, M.; Lisanti, M.P.; Chatterjee, V.K.; Lazar, M.A.; Pestell, R.G. Inhibition of Cellular Proliferation through Ikappab Kinase-Independent and Peroxisome Proliferator-Activated Receptor Gamma-Dependent Repression of Cyclin D1. Mol. Cell Biol. 2001, 21, 3057–3070. [Google Scholar] [CrossRef] [Green Version]
- Yu, H.N.; Noh, E.M.; Lee, Y.R.; Roh, S.G.; Song, E.K.; Han, M.K.; Lee, Y.C.; Shim, I.K.; Lee, S.J.; Jung, S.H.; et al. Troglitazone Enhances Tamoxifen-Induced Growth Inhibitory Activity of Mcf-7 Cells. Biochem. Biophys. Res. Commun. 2008, 377, 242–247. [Google Scholar] [CrossRef]
- Pignatelli, M.; Sanchez-Rodriguez, J.; Santos, A.; Perez-Castillo, A. 15-Deoxy-Delta-12,14-Prostaglandin J2 Induces Programmed Cell Death of Breast Cancer Cells by a Pleiotropic Mechanism. Carcinogenesis 2005, 26, 81–92. [Google Scholar] [CrossRef] [Green Version]
- Rovito, D.; Giordano, C.; Vizza, D.; Plastina, P.; Barone, I.; Casaburi, I.; Lanzino, M.; De Amicis, F.; Sisci, D.; Mauro, L.; et al. Omega-3 Pufa Ethanolamides Dhea and Epea Induce Autophagy through Ppargamma Activation in Mcf-7 Breast Cancer Cells. J. Cell Physiol. 2013, 228, 1314–1322. [Google Scholar] [CrossRef] [PubMed]
- Sun, H.; Berquin, I.M.; Owens, R.T.; O’Flaherty, J.T.; Edwards, I.J. Peroxisome Proliferator-Activated Receptor Gamma-Mediated up-Regulation of Syndecan-1 by N-3 Fatty Acids Promotes Apoptosis of Human Breast Cancer Cells. Cancer Res. 2008, 68, 2912–2919. [Google Scholar] [CrossRef] [Green Version]
- Michael, M.S.; Badr, M.Z.; Badawi, A.F. Inhibition of Cyclooxygenase-2 and Activation of Peroxisome Proliferator-Activated Receptor-Gamma Synergistically Induces Apoptosis and Inhibits Growth of Human Breast Cancer Cells. Int. J. Mol. Med. 2003, 11, 733–736. [Google Scholar] [PubMed]
- Elstner, E.; Muller, C.; Koshizuka, K.; Williamson, E.A.; Park, D.; Asou, H.; Shintaku, P.; Said, J.W.; Heber, D.; Koeffler, H.P. Ligands for Peroxisome Proliferator-Activated Receptorgamma and Retinoic Acid Receptor Inhibit Growth and Induce Apoptosis of Human Breast Cancer Cells in Vitro and in Bnx Mice. Proc. Natl. Acad. Sci. USA 1998, 95, 8806–8811. [Google Scholar] [CrossRef] [Green Version]
- Bonofiglio, D.; Cione, E.; Vizza, D.; Perri, M.; Pingitore, A.; Qi, H.; Catalano, S.; Rovito, D.; Genchi, G.; Ando, S. Bid as a Potential Target of Apoptotic Effects Exerted by Low Doses of Ppargamma and Rxr Ligands in Breast Cancer Cells. Cell Cycle 2011, 10, 2344–2354. [Google Scholar] [CrossRef] [Green Version]
- Zhou, J.; Zhang, W.; Liang, B.; Casimiro, M.C.; Whitaker-Menezes, D.; Wang, M.; Lisanti, M.P.; Lanza-Jacoby, S.; Pestell, R.G.; Wang, C. Ppargamma Activation Induces Autophagy in Breast Cancer Cells. Int. J. Biochem. Cell Biol. 2009, 41, 2334–2342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cheng, W.Y.; Huynh, H.; Chen, P.; Pena-Llopis, S.; Wan, Y. Macrophage Ppargamma Inhibits Gpr132 to Mediate the Anti-Tumor Effects of Rosiglitazone. Elife 2016, 5, e18501. [Google Scholar] [CrossRef] [Green Version]
- Gionfriddo, G.; Plastina, P.; Augimeri, G.; Catalano, S.; Giordano, C.; Barone, I.; Morelli, C.; Giordano, F.; Gelsomino, L.; Sisci, D.; et al. Modulating Tumor-Associated Macrophage Polarization by Synthetic and Natural Ppargamma Ligands as a Potential Target in Breast Cancer. Cells 2020, 9, 174. [Google Scholar] [CrossRef] [Green Version]
- Jang, H.Y.; Hong, O.Y.; Youn, H.J.; Kim, M.G.; Kim, C.H.; Jung, S.H.; Kim, J.S. 15d-Pgj2 Inhibits Nf-Kappab and Ap-1-Mediated Mmp-9 Expression and Invasion of Breast Cancer Cell by Means of a Heme Oxygenase-1-Dependent Mechanism. BMB Rep. 2020, 53, 212–217. [Google Scholar] [CrossRef]
- Augimeri, G.; Gelsomino, L.; Plastina, P.; Giordano, C.; Barone, I.; Catalano, S.; Ando, S.; Bonofiglio, D. Natural and Synthetic Ppargamma Ligands in Tumor Microenvironment: A New Potential Strategy against Breast Cancer. Int. J. Mol. Sci. 2020, 21, 9721. [Google Scholar] [CrossRef]
- Clay, C.E.; Namen, A.M.; Atsumi, G.; Willingham, M.C.; High, K.P.; Kute, T.E.; Trimboli, A.J.; Fonteh, A.N.; Dawson, P.A.; Chilton, F.H. Influence of J Series Prostaglandins on Apoptosis and Tumorigenesis of Breast Cancer Cells. Carcinogenesis 1999, 20, 1905–1911. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lapillonne, H.; Konopleva, M.; Tsao, T.; Gold, D.; McQueen, T.; Sutherland, R.L.; Madden, T.; Andreeff, M. Activation of Peroxisome Proliferator-Activated Receptor Gamma by a Novel Synthetic Triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid Induces Growth Arrest and Apoptosis in Breast Cancer Cells. Cancer Res. 2003, 63, 5926–5939. [Google Scholar]
- Jiang, W.; Zhu, Z.; McGinley, J.N.; El Bayoumy, K.; Manni, A.; Thompson, H.J. Identification of a Molecular Signature Underlying Inhibition of Mammary Carcinoma Growth by Dietary N-3 Fatty Acids. Cancer Res. 2012, 72, 3795–3806. [Google Scholar] [CrossRef] [Green Version]
- Burstein, H.J.; Demetri, G.D.; Mueller, E.; Sarraf, P.; Spiegelman, B.M.; Winer, E.P. Use of the Peroxisome Proliferator-Activated Receptor (Ppar) Gamma Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase Ii Study. Breast Cancer Res. Treat. 2003, 79, 391–397. [Google Scholar] [CrossRef] [PubMed]
- Yee, L.D.; Williams, N.; Wen, P.; Young, D.C.; Lester, J.; Johnson, M.V.; Farrar, W.B.; Walker, M.J.; Povoski, S.P.; Suster, S.; et al. Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-Term Therapy on Tumor Tissue and Serum Markers. Clin. Cancer Res. 2007, 13, 246–252. [Google Scholar] [CrossRef] [Green Version]
- Ansorge, N.; Dannecker, C.; Jeschke, U.; Schmoeckel, E.; Mayr, D.; Heidegger, H.H.; Vattai, A.; Burgmann, M.; Czogalla, B.; Mahner, S.; et al. Combined Cox-2/Ppargamma Expression as Independent Negative Prognosticator for Vulvar Cancer Patients. Diagnostics 2021, 11, 491. [Google Scholar] [CrossRef] [PubMed]
- Shao, W.; Kuhn, C.; Mayr, D.; Ditsch, N.; Kailuwait, M.; Wolf, V.; Harbeck, N.; Mahner, S.; Jeschke, U.; Cavailles, V.; et al. Cytoplasmic Ppargamma Is a Marker of Poor Prognosis in Patients with Cox-1 Negative Primary Breast Cancers. J. Trans. Med. 2020, 18, 94. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Augimeri, G.; Bonofiglio, D. PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy. Biomedicines 2021, 9, 543. https://doi.org/10.3390/biomedicines9050543
Augimeri G, Bonofiglio D. PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy. Biomedicines. 2021; 9(5):543. https://doi.org/10.3390/biomedicines9050543
Chicago/Turabian StyleAugimeri, Giuseppina, and Daniela Bonofiglio. 2021. "PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy" Biomedicines 9, no. 5: 543. https://doi.org/10.3390/biomedicines9050543